Medicinal Chemistry ACS Chemical Biology

Fluorinated AFMT analogs shield gut L-dopa from bacteria

  • AFMT, a mechanism-based inhibitor of the gut bacterial decarboxylases that destroy L-dopa, can itself be oxidized by human tyrosine hydroxylase, a host metabolic liability.
  • The authors modified AFMT's aryl ring (difluoro analogs) to dodge the host enzyme while keeping activity on the bacterial target.
  • In vitro, the analogs resisted tyrosine hydroxylase turnover yet still blocked bacterial L-dopa metabolism; they are pitched as starting points for animal studies.
Points Based on the abstract

Fixing the host liability rather than simply dosing more inhibitor is a smart move; carbidopa and benserazide work because they stay out of the gut-bacteria fight. But this is in vitro only: gut exposure, absorption of the fluorinated analogs and microbiome side effects are unknown. Next I'd want SAR on bacterial decarboxylase versus tyrosine hydroxylase, then animal PK.